{"id":42376,"date":"2023-10-16T10:54:48","date_gmt":"2023-10-16T08:54:48","guid":{"rendered":"https:\/\/osaraba.eus\/infoberriak\/?p=42376"},"modified":"2023-10-16T10:54:48","modified_gmt":"2023-10-16T08:54:48","slug":"inmunizacion-frente-a-virus-respiratorio-sincitial-vrs-en-euskadi","status":"publish","type":"post","link":"https:\/\/osaraba.eus\/infoberriak\/es\/inmunizacion-frente-a-virus-respiratorio-sincitial-vrs-en-euskadi\/","title":{"rendered":"Inmunizaci\u00f3n frente a Virus Respiratorio Sincitial (VRS) en Euskadi"},"content":{"rendered":"<h4><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-42380 size-full\" src=\"https:\/\/i0.wp.com\/osaraba.eus\/infoberriak\/wp-content\/uploads\/2023\/10\/VRS_O.jpg?resize=775%2C367\" alt=\"\" width=\"775\" height=\"367\" srcset=\"https:\/\/i0.wp.com\/osaraba.eus\/infoberriak\/wp-content\/uploads\/2023\/10\/VRS_O.jpg?w=775&amp;ssl=1 775w, https:\/\/i0.wp.com\/osaraba.eus\/infoberriak\/wp-content\/uploads\/2023\/10\/VRS_O.jpg?resize=300%2C142&amp;ssl=1 300w, https:\/\/i0.wp.com\/osaraba.eus\/infoberriak\/wp-content\/uploads\/2023\/10\/VRS_O.jpg?resize=768%2C364&amp;ssl=1 768w, https:\/\/i0.wp.com\/osaraba.eus\/infoberriak\/wp-content\/uploads\/2023\/10\/VRS_O.jpg?resize=520%2C245&amp;ssl=1 520w, https:\/\/i0.wp.com\/osaraba.eus\/infoberriak\/wp-content\/uploads\/2023\/10\/VRS_O.jpg?resize=720%2C340&amp;ssl=1 720w\" sizes=\"auto, (max-width: 775px) 100vw, 775px\" \/><\/h4>\n<h4 style=\"text-align: center;\">Recientemente se ha autorizado el uso de un nuevo producto inmunizante frente a VRS<\/h4>\n<p style=\"text-align: justify;\">Se trata de un anticuerpo monoclonal humanizado, Nirsevimab, capaz de neutralizar tanto al VRS-A como al VRS-B. Presenta un buen perfil de eficacia y seguridad.<\/p>\n<p style=\"text-align: justify;\">El Departamento de Salud, siguiendo las recomendaciones del Consejo Asesor de Vacunaciones de Euskadi, ha incluido la inmunizaci\u00f3n con Nirsevimab durante la temporada de VRS 2023-2024, en la poblaci\u00f3n infantil, priorizando a la poblaci\u00f3n con alto riesgo de enfermedad grave por VRS e incorporando a los reci\u00e9n nacidos sanos durante la temporada de circulaci\u00f3n de VRS.<\/p>\n<p style=\"text-align: center;\"><div class=\"su-button-center\"><a href=\"http:\/\/osaraba.eus\/infoberriak\/wp-content\/uploads\/2023\/10\/Nota-inmunizacion-VRS-Nirsevimab-Osakidetza_13.10.2023.pdf\" class=\"su-button su-button-style-flat\" style=\"color:#FFFFFF;background-color:#2d73ef;border-color:#245cc0;border-radius:7px\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"color:#FFFFFF;padding:7px 20px;font-size:16px;line-height:24px;border-color:#6c9df4;border-radius:7px;text-shadow:none\"><i class=\"sui sui-file-pdf-o\" style=\"font-size:16px;color:#FFFFFF\"><\/i> Descargar nota informativa<\/span><\/a><\/div>\n<div class=\"su-spacer\" style=\"height:10px\"><\/div>\n<a href=\"https:\/\/osaraba.eus\/infoberriak\/wp-content\/uploads\/2023\/10\/Nota-inmunizacion-VRS-Nirsevimab-Osakidetza_13.10.2023.pdf\" class=\"pdfemb-viewer\" style=\"\" data-width=\"max\" data-height=\"max\" data-toolbar=\"bottom\" data-toolbar-fixed=\"off\">Nota inmunizaci\u00f3n VRS Nirsevimab-Osakidetza_13.10.2023<\/a>\n","protected":false},"excerpt":{"rendered":"<p>Recientemente se ha autorizado el uso de un nuevo producto inmunizante frente a VRS.<\/p>\n","protected":false},"author":6,"featured_media":42380,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[958],"tags":[474],"class_list":["post-42376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-portada","tag-vacunas"],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/osaraba.eus\/infoberriak\/wp-content\/uploads\/2023\/10\/VRS_O.jpg?fit=775%2C367&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/paCxCe-b1u","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/posts\/42376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/comments?post=42376"}],"version-history":[{"count":0,"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/posts\/42376\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/media\/42380"}],"wp:attachment":[{"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/media?parent=42376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/categories?post=42376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/osaraba.eus\/infoberriak\/wp-json\/wp\/v2\/tags?post=42376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}